History
Primary biliary cholangitis has been characterized as a chronic disease in which the very small bile ducts within the liver are gradually destroyed, causing bile to stagnate, and over time scar tissue builds up in the liver, which can lead to cirrhosis. Long ago, patients were often found in a state of advanced liver disease with jaundice and ascites, so the name of the disease included "cirrhosis," and in fact the term "primary biliary cirrhosis" was widely used. However, it became clear that the key site of damage in this disease is the "bile ducts" from the early stage. In other words, cirrhosis is only a result that appears at the end stage of the disease; the disease itself begins with chronic inflammation and destruction of the small bile ducts.
As this understanding spread, in the 2010s the term "primary biliary cholangitis" was widely adopted, dropping cirrhosis from the name of the disease to reflect the point that "cirrhosis is not always present." It is also historically significant that patient organizations strongly proposed the change in terminology. An important turning point in the history of diagnosis was the establishment of the "antimitochondrial antibody" test. As it became known that a specific autoantibody is detected in the blood at a very high rate, it became possible to distinguish this disease relatively clearly among cholestatic diseases of unknown cause.
In terms of treatment, the biggest change was the establishment of ursodiol (ursodeoxycholic acid) as the standard treatment. Before this drug was introduced, the rate of progression to cirrhosis was high, but as early diagnosis and drug treatment spread, the number of patients who "live a long time without a transplant" increased greatly. Recent research concludes that strategies for identifying early those who do not respond sufficiently to standard treatment and adding second-line treatment, and approaches that treat symptoms such as itching and fatigue as independent treatment goals, are being strengthened.
Causes
The cause of primary biliary cholangitis has not been pinned down to a single factor. The essence of the disease is that it is an "immune-mediated" disease in which the immune system attacks one's own small bile ducts, causing chronic inflammation. In this process, genetic predisposition and environmental factors are understood to act together. The most typical feature is that antimitochondrial antibodies are detected at a high rate. In addition, other autoimmune diseases such as thyroid disease, rheumatoid arthritis, and Sjögren's syndrome sometimes appear together, so it is highly likely that a systemic vulnerability in immune regulation lies in the background.
As environmental factors, the hypothesis that certain infections or chemical exposures can act as a "trigger" has long been discussed. The concept of "molecular mimicry" frequently comes up; this is the explanation that an immune response against components of external microorganisms may happen to attack structures similar to the body's own proteins and thereby turn into an autoimmune response. However, which environmental factors are actually important, and what determines onset in which people, has not yet been fully elucidated.
Recent research concludes that bile duct cells are not simply victims, and that damage can be accelerated when their secretory function that protects them from the toxicity of bile acids (the bile duct's "bicarbonate umbrella") breaks down. In other words, the disease can persist in a form in which immune attack and bile acid toxicity reinforce each other.
Genetic Epidemiology
Primary biliary cholangitis is not a single-gene disease, but through occurrence within families, twin studies, and gene association studies, it has become relatively certain that genetic predisposition exists. In particular, research has accumulated showing that the human leukocyte antigen family, which regulates immune responses, and genes in several immune signaling pathways (for example, cytokine-related pathways) are linked to risk. However, genetics alone cannot explain onset. This is because many people with the same genetic predisposition do not develop the disease, and living environments and exposure factors can differ greatly. Therefore, it is more natural to view it as the result of a combination of "genetic susceptibility + environmental trigger + failure of immune regulation."
A practically important point in genetic epidemiology is "clustering with other autoimmune diseases." A variety of autoimmune diseases may appear in the family history, and the patient may also have several autoimmune diseases at the same time.
This background is meaningful not so much for identifying the cause as for advancing the diagnosis in suspicious situations and managing comorbidities together. Understanding the tendency toward autoimmune clustering plays an important role in establishing the overall care plan.
General Epidemiology
Primary biliary cholangitis is a relatively rare disease, but as diagnoses have increased, its presence in clinical practice has grown. It is generally common in middle-aged women and is known as a disease with a very high female-to-male ratio. However, recent research concludes that male patients may not be as few as previously thought, and that the sex ratio may vary depending on diagnostic criteria and access to medical care. In the early stage, there are often no symptoms, and it is frequently found through abnormal blood test results. Therefore, the actual scale of prevalence may be larger than "the number of diagnosed patients," and how well primary care tracks and refers cholestatic liver test abnormalities affects the diagnosis rate.
Another epidemiologically important point is the diversity of prognosis. Some people respond well to treatment and live nearly normally, but if the response to treatment is insufficient, fibrosis progresses and the risk of cirrhosis and liver failure increases. Therefore, it is realistic to look not only at simple prevalence but also at "the proportion of treatment responders and nonresponders."
Recent research emphasizes a management strategy in which the biochemical response at 1 year after ursodiol treatment is strongly linked to long-term prognosis, and second-line treatment should be considered more actively for those whose response is insufficient.
Pathogenesis
The pathogenesis of primary biliary cholangitis can be understood as "a process in which an immune response targeting the small bile ducts is repeated, the bile ducts disappear, bile stagnates, and as a result scar tissue builds up in the liver." Under the microscope, immune cells gather around the bile ducts and cause inflammation, and in some cases inflammatory clusters such as granulomas are observed. Immunologically, both T-cell and B-cell responses are involved. Specific antibodies such as antimitochondrial antibodies are well known, but the actual tissue damage is understood as the result of cellular immune responses and inflammatory signals acting together.
A concept frequently mentioned in recent research is the bile duct's "bicarbonate umbrella." Bile duct cells secrete bicarbonate to protect themselves from the toxicity of bile acids, and when this defensive barrier weakens, bile acids can more easily enter bile duct cells and cause damage. When the bile ducts are weakened by immune attack and bile acid toxicity is added, a vicious cycle of accelerating damage arises.
There is also a hypothesis that genetic and epigenetic changes and environmental factors can act in a direction that breaks immune tolerance. It is understood that the core of the disease is a state, created by the combination of these multiple factors, in which "an immune response targeting the bile ducts, once switched on, does not switch off" and persists for a long period.
Symptoms
The symptoms of primary biliary cholangitis often begin quietly. In the early stage, it is common to have no symptoms at all or only persistent fatigue. Therefore, it is often diagnosed by further testing after cholestatic liver test abnormalities are found at a health checkup. The typical symptoms are fatigue and itching. Itching can be worse at night and can disturb sleep, further worsening fatigue. Dry eyes and dry mouth sometimes appear together, which may be related to an accompanying autoimmune disease.
As the disease progresses, symptoms of cirrhosis and liver failure may appear, such as jaundice, weight loss, abdominal distension (ascites), leg swelling, easy bruising, and changes in consciousness. If cholestasis persists for a long time, fat absorption decreases, which can lead to deficiencies of fat-soluble vitamins, and bones can weaken, increasing the risk of fractures.
Recent research concludes that because fatigue is not simply proportional to liver function values and can greatly affect quality of life and prognosis, it is important to evaluate it systematically and to check accompanying conditions (anemia, hypothyroidism, depression, and others) at the same time.
Signs
A cholestatic pattern on blood tests is an important sign. Elevations of alkaline phosphatase and gamma-glutamyl transferase can appear from the early stage, and as the disease progresses, elevated bilirubin may accompany them. An increase in immunoglobulin M can also be a clue. The most characteristic sign is a positive antimitochondrial antibody. This antibody is detected in many patients, and certain subtypes (for example, M2) are known to have greater diagnostic significance. Even if antimitochondrial antibodies are negative, certain antinuclear antibodies (for example, sp100, gp210) can help in diagnosis.
On physical examination, scratch marks, jaundice, and, in advanced cases, signs of chronic liver disease such as ascites or splenomegaly may be observed. As cholesterol rises, fatty deposits may form around the eyelids (xanthomas, xanthelasma).
A biopsy is not always necessary, but it provides important information when the diagnosis is unclear, when autoimmune hepatitis is also suspected, or when another liver disease may be present. In the tissue, chronic inflammation around the small bile ducts, loss of bile ducts, and the degree of fibrosis can be confirmed.
Screening
Primary biliary cholangitis is not common enough to warrant broad screening of the general population. Instead, it is realistic to carry out selective evaluation centered on situations "when cholestatic liver test abnormalities cannot be explained." The first step is to check the blood test pattern. If elevations of alkaline phosphatase and gamma-glutamyl transferase persist, other causes such as medications, gallstones or biliary obstruction, and viral hepatitis are checked first. The second is antimitochondrial antibody testing. When there is cholestasis of unknown cause, checking for the antibody can set the direction of diagnosis relatively quickly.
If antimitochondrial antibodies are negative, the likelihood of diagnosis can be increased by additionally checking other autoantibodies such as sp100 and gp210. The third is ruling out "blocked bile ducts" (extrahepatic biliary obstruction) with imaging. Tests such as ultrasound and magnetic resonance cholangiopancreatography are used.
Recent research concludes that because early diagnosis and early treatment change the natural course, it is important to connect to specialist evaluation when test abnormalities recur, even in the absence of symptoms.
Diagnosis
Diagnosis is usually made by combining three pillars: 1) cholestatic liver test abnormalities, 2) a positive antimitochondrial antibody or autoantibody specific to primary biliary cholangitis, and 3) liver biopsy findings when necessary. In many cases, meeting two or more of these supports the diagnosis. Imaging is important for ruling out other causes such as biliary obstruction. When it must be distinguished from diseases in which the large bile ducts narrow irregularly, such as primary sclerosing cholangitis, magnetic resonance cholangiopancreatography is helpful.
A biopsy is useful when antibodies are absent, when an "overlap syndrome" with coexisting autoimmune hepatitis is suspected, or when another liver disease such as steatohepatitis may be present. It can also confirm the degree of fibrosis, which serves as a reference for assessing prognosis and deciding treatment intensity.
Recent research and clinical guidelines conclude that when antibody positivity and typical test findings are present, diagnosis is often possible without a biopsy, but in exceptional situations biopsy still plays an important role.
Treatment
The main goals of treatment are 1) to slow the progression of the disease and reduce the risk of liver transplantation, 2) to improve quality of life by managing symptoms such as itching and fatigue, and 3) to prevent complications such as osteoporosis and vitamin deficiencies. The standard first-line treatment is ursodiol (ursodeoxycholic acid). It is usually taken long term at a weight-based dose, and the response is evaluated at about the 1-year point to see whether liver test values improve. If the response is good, the long-term prognosis can be very good.
If the response is insufficient, second-line treatment is considered. Obeticholic acid, fibrate drugs, and, more recently, new drugs in the peroxisome proliferator-activated receptor (PPAR) agonist class are mentioned. For symptom treatment, bile acid sequestrants (such as cholestyramine) are used first-line for itching, and if there is no response, other drugs are considered step by step. Fatigue is rarely resolved by any single drug; the main strategy is to find and correct accompanying factors such as anemia, hypothyroidism, depression, and sleep disorders, and to preserve daily functioning.
Recent research concludes that as second-line treatment options have increased, the importance of "personalized treatment" has grown. If end-stage liver failure or recurrent complications develop, liver transplantation can be the definitive treatment.
Prognosis
The prognosis depends greatly on whether there is a response to treatment. Reports have continued that with a good biochemical response to ursodiol, survival can approach that of the general population. Conversely, if the response is insufficient, the risk of progression of fibrosis, cirrhosis, and liver failure increases. When assessing prognosis, values such as bilirubin are especially important. Elevated bilirubin can suggest advanced disease and is often associated with long-term prognosis. In addition, how far fibrosis has progressed, the state of liver function at the start of treatment, male sex, age at onset, and other factors affect the prognosis.
Symptoms are also not unrelated to prognosis. Recent research shows that severe fatigue not only greatly reduces quality of life, but some studies have also discussed a possible association with prognosis. Severe itching has a large effect on sleep and mental health, so management is needed.
In addition, managing accompanying problems such as osteoporosis, fat-soluble vitamin deficiencies, and thyroid disease well determines long-term health. If cirrhosis develops, standard cirrhosis management, such as surveillance for varices, ascites, and liver cancer, is needed.
Prevention
Primary biliary cholangitis is not a disease that can be prevented by vaccination like an infectious disease, so prevention, defined realistically, means "early detection and prevention of worsening." First, not neglecting unexplained cholestatic liver test abnormalities is the most important prevention strategy. Even if there are no symptoms, if test abnormalities persist, diagnosing early through antimitochondrial antibody testing and imaging and starting treatment slows progression. Second, after diagnosis, regularly checking the response to treatment and considering second-line treatment at the appropriate time if the response is insufficient constitutes prevention of worsening.
Third, preventing complications is important. Systematic follow-up is needed, such as bone density assessment and vitamin supplementation, thyroid function tests, and surveillance for varices and liver cancer in patients with cirrhosis. Because quality of life drops greatly if itching and fatigue are neglected, it is realistic to regard symptom treatment as part of prevention as well.
Recent research concludes that as new second-line treatments and symptom-relieving drugs increase, intensifying treatment at the appropriate time may further improve long-term prognosis.